

Decapeptide-12

Cat. No.:	HY-P0096
CAS No.:	137665-91-9
Molecular Formula:	K_3W_3
Molecular Weight:	1395.52
Sequence Shortening:	YRSRKYSSWY
Target:	Tyrosinase; Sirtuin
Pathway:	Metabolic Enzyme/Protease; Cell Cycle/DNA Damage; Epigenetics
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

BIOLOGICAL ACTIVITY

Description	Decapeptide-12, a small oligopeptide, is a tyrosinase inhibitor that interacts with C-terminal residue of tyrosinase (K_d : 61.1 μ M). Decapeptide-12 is a competitive inhibitor of mushroom tyrosinase (IC_{50} : 40 μ M). Decapeptide-12 also increases transcription of SIRT. Decapeptide-12 reduces melanin content in melanocytes. Decapeptide-12 is used for the research of melanogenesis, senescence, inflammation ^{[1][2][3]} .												
IC_{50} & Target	IC_{50} : 40 μ M (Tyrosinase) ^[1] , K_d : 61.1 μ M (Tyrosinase) ^[2] .												
In Vitro	<p>Decapeptide-12 (P4, 0.01-10 mM) dose-dependently inhibits mushroom tyrosinase with an IC_{50} value of 40 μM, and inhibits human tyrosinase by 25-35% at 100 μM^[1].</p> <p>Decapeptide-12 (100 μM, 7 days) leads to 43% reduction in melanin content in melanocytes with no effect on cell proliferation^[1].</p> <p>Decapeptide-12 (peptide P4, 0-400 μM) inhibits the monophenolase reaction with an IC_{50} value of 123 μM^[2].</p> <p>Decapeptide-12 interact with tyrosinase with a K_d value of 61.1 μM^[2].</p> <p>Decapeptide-12 (100 μM, 72 h) increases transcription of SIRT1, SIRT3, SIRT6, and SIRT7 with reduced cytotoxicity in human neonatal keratinocyte progenitors^[3].</p> <p>Decapeptide-12 (0-1 mM, 72 h) reduces Phytohemagglutinin (PHA)-stimulated PBMC cells proliferation^[3].</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <p>Cell Proliferation Assay^[3]</p> <table border="1"> <tr> <td>Cell Line:</td> <td>Phytohemagglutinin (PHA)-stimulated PBMC cells</td> </tr> <tr> <td>Concentration:</td> <td>0, 0.025, 0.05, 0.1, 0.3, 1 mM</td> </tr> <tr> <td>Incubation Time:</td> <td>72 h</td> </tr> <tr> <td>Result:</td> <td>Reduced cell proliferation by 28% at 0.05 mM and 54% at 0.1 mM.</td> </tr> </table> <p>RT-PCR^[3]</p> <table border="1"> <tr> <td>Cell Line:</td> <td>Human neonatal keratinocyte progenitors</td> </tr> <tr> <td>Concentration:</td> <td>3, 10, 30, 50, 100, 300, 500, 1000 μM</td> </tr> </table>	Cell Line:	Phytohemagglutinin (PHA)-stimulated PBMC cells	Concentration:	0, 0.025, 0.05, 0.1, 0.3, 1 mM	Incubation Time:	72 h	Result:	Reduced cell proliferation by 28% at 0.05 mM and 54% at 0.1 mM.	Cell Line:	Human neonatal keratinocyte progenitors	Concentration:	3, 10, 30, 50, 100, 300, 500, 1000 μ M
Cell Line:	Phytohemagglutinin (PHA)-stimulated PBMC cells												
Concentration:	0, 0.025, 0.05, 0.1, 0.3, 1 mM												
Incubation Time:	72 h												
Result:	Reduced cell proliferation by 28% at 0.05 mM and 54% at 0.1 mM.												
Cell Line:	Human neonatal keratinocyte progenitors												
Concentration:	3, 10, 30, 50, 100, 300, 500, 1000 μ M												

Incubation Time:	72 h
Result:	Increased transcription of SIRT1 by 141% relative to untreated cells, increased SIRT3, SIRT6 and SIRT7 by 121%, 147% and 95%, respectively.

REFERENCES

- [1]. Anan Abu Ubeid, et al. Short-sequence oligopeptides with inhibitory activity against mushroom and human tyrosinase. *J Invest Dermatol.* 2009 Sep;129(9):2242-9.
- [2]. Akihito Ochiai, et al. New tyrosinase inhibitory decapeptide: Molecular insights into the role of tyrosine residues. *J Biosci Bioeng.* 2016 Jun;121(6):607-613.
- [3]. Basil M H, et al. Tyrosinase inhibitors with potent anti-senescence activity in human neonatal keratinocyte progenitors. *J Dermatol Surg Res Ther,* 2019, 2019: 30-39.
-

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA